SWX:ROPPharmaceuticals
Roche (SWX:ROP) Wins Priority Review For Gazyva And Launches First Automated HDV Test
In July 2026, Roche Holding received US FDA Priority Review for Gazyva/Gazyvaro in primary membranous nephropathy, a condition with no FDA approved therapies.
Roche also launched the cobas HDV test, described as the first fully automated, high throughput diagnostic assay for Hepatitis D Virus.
Both developments add to Roche Holding's immunology and virology portfolio and target areas with significant unmet medical need.
For investors tracking Roche Holding (SWX:ROP), these July 2026...